The Firm will Host a Convention Name and Webcast on Thursday, August 8, 2024, at 8:30 AM ET
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) — Catalyst Prescription drugs, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical firm centered on in-licensing, creating, and commercializing novel medicines for sufferers residing with uncommon and difficult-to-treat illnesses, at the moment introduced that it’s going to launch its second quarter 2024 monetary outcomes after the market shut on Wednesday, August 7, 2024.
Catalyst’s administration group will host a convention name and webcast on Thursday, August 8, 2024, at 8:30 AM ET to debate the Firm’s monetary outcomes and supply a enterprise replace.
Convention Name & Webcast Particulars
| Date: Time: US/Canada Dial-in Quantity: Worldwide Dial-in Quantity: |
August 8, 2024 8:30 AM ET (877) 407-8912 (201) 689-8059 |
The webcast will likely be accessible underneath the Buyers part on the Firm’s web site at www.catalystpharma.com. A webcast replay will likely be out there on the Catalyst web site for at the least 30 days following the date of the occasion.
About Catalyst Prescription drugs, Inc.
With distinctive affected person focus, Catalyst is dedicated to creating and commercializing modern first-in-class medicines that tackle uncommon and difficult-to-treat illnesses. Catalyst’s flagship U.S. industrial product is FIRDAPSE ® (amifampridine) Tablets 10 mg, permitted for the remedy of Lambert-Eaton myasthenic syndrome (“LEMS”) in adults and pediatric sufferers 6 years of age and older. In January 2023, Catalyst acquired the U.S. industrial rights to FYCOMPA ® (perampanel) CIII, a prescription drugs permitted in folks with epilepsy aged 4 and older alone or with different medicines to deal with partial-onset seizures with or with out secondarily generalized seizures and with different medicines to deal with main generalized tonic-clonic seizures for folks with epilepsy aged 12 and older. Additional, Canada’s nationwide healthcare regulatory company, Well being Canada, has permitted the usage of FIRDAPSE for the remedy of grownup sufferers in Canada with LEMS. On July 18, 2023, Catalyst acquired an unique license for North America for AGAMREE ® (vamorolone) oral suspension 40 mg/mL, a novel corticosteroid remedy for Duchenne Muscular Dystrophy. AGAMREE beforehand acquired FDA Orphan Drug and Quick Observe designations and was permitted by the FDA for commercialization within the U.S. on October 26, 2023. AGAMREE grew to become commercially out there by prescription within the U.S. on March 13, 2024.
For extra details about Catalyst Prescription drugs, Inc., please go to the Firm’s web site at¯www.catalystpharma.com. For Full Prescribing and Security Data for FIRDAPSE ®, please go to www.firdapse.com. For Full Prescribing Data, together with Boxed WARNING for FYCOMPA ®, please go to www.fycompa.com. For Full Prescribing Data for AGAMREE ®, please go to www.agamree.com.
Ahead-Wanting Statements
This press launch comprises forward-looking statements, as that time period is outlined within the Personal Securities Litigation Reform Act of 1995. Ahead-looking statements contain recognized and unknown dangers and uncertainties, which can trigger Catalyst’s precise ends in future intervals to vary materially from forecasted outcomes. A lot of components, together with these components described in Catalyst’s Annual Report on Kind 10-Ok for the fiscal 12 months 2023 and its different filings with the U.S. Securities and Change Fee (“SEC”), may adversely have an effect on Catalyst. Copies of Catalyst’s filings with the SEC can be found from the SEC, could also be discovered on Catalyst’s web site, or could also be obtained upon request from Catalyst. Catalyst doesn’t undertake any obligation to replace the knowledge contained herein, which speaks solely as of this date.
Supply: Catalyst Prescription drugs, Inc.
